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Members of the Fos protein family dimerise with Jun proteins to form the AP-1 transcription factor complex. They have a central
function in proliferation and differentiation of normal tissue as well as in oncogenic transformation and tumour progression. We
analysed the expression of c-Fos, FosB, Fra-1 and Fra-2 to investigate the function of Fos transcription factors in ovarian cancer. A
total of 101 patients were included in the study. Expression of Fos proteins was determined by western blot analysis, quantified by
densitometry and verified by immunohistochemistry. Reduced c-Fos expression was independently associated with unfavourable
progression-free survival (20.6, 31.6 and 51.2 months for patients with low, moderate and high c-Fos expression; P¼0.003) as well as
overall survival (23.8, 46.0 and 55.5 months for low, moderate and high c-Fos levels; P¼0.003). No correlations were observed for
FosB, Fra-1 and Fra-2. We conclude that loss of c-Fos expression is associated with tumour progression in ovarian carcinoma and that
c-Fos may be a prognostic factor. These results are in contrast to the classic concept of c-Fos as an oncogene, but are supported by
the recently discovered tumour-suppressing and proapoptotic function of c-Fos in various cancer types.
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Ovarian cancer accounts for the highest tumour-related mortality
among women with gynaecologic malignancies. The American
Cancer Society estimates about 23000 new cases of ovarian cancer
each year in the United States and that 70% of the affected women
will die from their disease (American-Cancer-Society, 2007).
Although aggressive surgical cytoreduction and platinum-based
combination chemotherapy have improved outcome for many
patients, long-term survival could not generally be improved.
Identification of additional prognostic factors could help to stratify
patients into different biological subgroups. In ovarian cancer, this
is especially important for the group of patients with early relapse
(within 6 months after first-line treatment) that usually die within
6–12 months (du Bois et al, 2003). These patients (approximately
25%) do not benefit from current treatment modalities while
suffering from the sometimes severe side effects of therapy.
Subsequent research could then focus on the establishment of
more targeted and individual treatment strategies in this subgroup,
as previously shown for Her2/neu expression and trastuzumab
treatment in breast cancer (Pegram et al, 2000).
Widely accepted prognostic factors in patients with epithelial
ovarian cancer are International Federation of Gynecology and
Obstetrics (FIGO) stage and residual tumour volume after primary
surgical cytoreduction (Bristow et al, 2002; Tingulstad et al, 2003).
Several other clinical and biological factors such as age,
performance status, tumour histology and grade have been
assessed for prognostic significance over the past decades, but
none of them yielded conclusive and reproducible results (Omura
et al, 1991; Hornung et al, 2004; Winter et al, 2007).
Recent efforts to develop accurate predictors of clinical outcome
have mainly focused on assessment of global gene expression by
DNA microarrays. This technology provided information on
differential gene expression in a number of tumours including
ovarian cancer (Hartmann et al, 2005) and has identified gene
profiles associated with early relapse and decreased survival
(Spentzos et al, 2004). Members of the Fos family (c-Fos, FosB,
Fra-1 (Fos-related antigen 1) and Fra-2) are often represented in
these profiles (Meinhold-Heerlein et al, 2005). They dimerise with
the gene products of c-Jun, JunB or JunD to form the transcription
factor Activating Protein 1 (AP-1). AP-1 binds to the promoter
region of specific target genes, converting extracellular signals into
changes of gene expression (Milde-Langosch, 2005). As a member
of AP-1, c-Fos has been implicated mainly in signal transduction,
cell differentiation and proliferation (Shaulian and Karin, 2001).
Many studies focused on its oncogenic functions and found that
c-Fos regulated genes important for tumorigenesis, causing the
downregulation of tumour-suppressor genes (Bakin and Curran,
1999) and leading to invasive growth of cancer cells (Hu et al,
1994). Furthermore, c-Fos can induce a loss of cell polarity and
epithelial-mesenchymal transition, leading to invasive and meta-
static growth in mammary epithelial cells (Fialka et al, 1996).
In addition to these experimental results, several reports
investigated the function of c-Fos expression in human tumour
tissue. In osteosarcoma and endometrial carcinoma, c-Fos over-
expression was associated with high-grade lesions and adverse
outcome (Gamberi et al, 1998; Bamberger et al, 2001). In a
comparative analysis between precancerous lesion of the
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scervix uteri and invasive cervical cancer, c-Fos expression was
significantly lower in precancerous lesions (Prusty and Das, 2005).
C-Fos has also been identified as independent predictor of
decreased survival in breast cancer (Bland et al, 1995).
However, some more recent studies have raised the idea that
c-Fos may also have tumour-suppressor activity and might have a
function in apoptosis (Teng, 2000). Overexpression of c-Fos was
found to inhibit cell cycle progression, stimulated murine
hepatocyte cell death and strongly suppressed tumour formation
in vivo (Mikula et al, 2003). A functional involvement of c-Fos in
apoptosis has been shown by its regulatory involvement during
remodelling and stress response in various tissues in mouse
development (Jochum et al, 2001).
Besides c-Fos, FosB, Fra-1 and Fra-2 have also been shown to
have a function in progression of various tumour types: FosB is
downregulated in poorly differentiated mammary carcinomas
(Bamberger et al, 1999), whereas Fra-1 and, partly, Fra-2
overexpression leads to enhanced tumour cell motility and
invasion in breast cancer, colorectal cancer and mesothelioma
(Milde-Langosch, 2005).
This study investigated the potential function of Fos transcrip-
tion factors in ovarian cancer and analysed the expression and
prognostic significance of c-Fos, FosB, Fra-1 and Fra-2 in patients
with invasive epithelial ovarian carcinoma.
MATERIALS AND METHODS
Patients
Patients with epithelial ovarian carcinoma who presented for
primary surgery at the University Medical Center Hamburg-
Eppendorf between 1997 and 2006 were included in this study.
Thus, a total of 101 patients were retrospectively analysed. Detailed
patient characteristics are listed in Table 1. Clinicopathologic
factors were evaluated by reviewing medical charts and pathologic
records. Tissue slides were reviewed for histological classification
and clinical outcome was followed from the date of surgery to the
date of death or until the end of 2007. Two cases were lost to
follow-up right after surgery and were excluded from the survival
analysis. All patients gave written informed consent to access their
tissue and review their medical records according to our
investigational review board and ethics committee guidelines.
Tissue samples
Fresh-frozen samples were obtained intraoperatively and immedi-
ately stored at  801C. The histological characteristics of each
sample were assessed on cryo-cut and haematoxylin-eosin-stained
sections and the tissue was trimmed if necessary to obtain at least
70% tumour cells in the sample used for protein extraction.
Protein extraction
Samples of approximately 100mg were cut from the tissue and
pulverised using a micro-dismembrator (Braun-Melsungen, Mel-
sungen, Germany) for 2 45s at 200r.p.m. Proteins were lysed in
ice-cold sample buffer (50mM Tris pH 6.8, 1% sodium dodecyl
sulphate (SDS), 10% sucrose and 10mlml
 1 protease inhibitor
cocktail (Sigma, Taufkirchen, Germany)), and protein concentra-
tion was determined following the standard protocols and using
bovine serum albumin protein standards as described previously
(Bamberger et al, 1999; Milde-Langosch et al, 2005).
Western blot analysis
Equal amounts of protein (20mg) of each sample were loaded per
well, and equal loading was verified by immunoblotting with actin
antibodies (Santa Cruz, Heidelberg, Germany). As control samples,
proteins from the ovarian cancer cell lines Ovcar5 and Ovcar8 and
the breast cancer cell line MCF7 were loaded on each gel. After
electrophoresis, blotting to polyvinylidene difluoride membranes
and overnight incubation at 41C in blocking solution, membranes
were incubated for 1h at room temperature with the following
primary antibodies (all from Santa Cruz): c-Fos polyclonal
antibody no. 4 (1:1000), FosB polyclonal antibody no.102
(1:200), Fra-1 polyclonal antibody no. R-20 (1:400) and Fra-2
Table 1 Patient characteristics
No. of patients 101
Age (years)
Mean 59.2
Median 61
Range 21–87
FIGO stage
I1 0
II 8
III 60
IV 23
Grading
16
22 9
35 8
Not determined/unknown 8
Lymph node metastasis
N0 31
N1 55
NX 15
Residual tumour after surgery
Microscopic 67
o0.5cm 7
0.5–1cm 10
1–2cm 2
42cm 6
Not determined/unknown 9
Histologic subtype
Serous 74
Mucinous 6
Endometrioid 5
Clear cell 1
Undifferentiated 7
Mixed differentiation 8
Platinum-based first-line chemotherapy
Adjuvant 90
Neoadjuvant 6
None/unknown 5
CA 125 before surgery (kUl
 1)
Mean 2178
Median 436
Range 21–47000
Survival (months), n¼99
Progression-free survival
Mean 19.7
Median 15.2
Range 0.4–98
Overall survival
Mean 24.4
Median 20
Range 0.4–98
FIGO¼International Federation of Gynecology and Obstetrics; kU/l¼kilo Units per
liter.
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spolyclonal antibody no. Q-20 (1:800). As secondary antibody,
peroxidase-conjugated anti-rabbit-IgG (1:4000) was used, which
was visualised by chemiluminescence reagent (Super Signal West
Pico kit, Pierce, Rockfort, IL, USA) using Hyperfilm ECL films
(Amersham, Braunschweig, Germany). Band intensities were
quantified by densitometry (GS-700 Imaging Densitometer,
BioRad, Munich, Germany). Intensities of the specific protein
bands were calculated as percent intensity of the control sample
and corrected for equal actin loading as previously described
(Bamberger et al, 1999).
Immunohistochemistry
Serial sections of 4–6mm were deparaffinised in xylene,
rehydrated and microwaved for 20min in 20mM Tris, 10mM
citrate, 13mM EDTA, pH 7.8. After cooling down for 20min, the
slides were washed in TBS (50mM Tris, 150mM NaCl, pH 7.4),
blocked for 30min at room temperature with normal serum
(rabbit IgG, ABC Kit, Vector Laboratories, Burlingale, CA, USA),
diluted 1:20 in TBS and then incubated overnight at 41C with the
same c-Fos antibody used for western blots, diluted 1:100. After
washing, slides were reacted with biotin-labelled anti-mouse or
anti-rabbit immunoglobulin (IgG), incubated with preformed
ABC-complex (Vectastain, Vector Laboratories) and detected with
DAB-substrate kit (Vectastain, Vector Laboratories). The slides
were counterstained with hematoxylin. For negative controls the
primary antibody was omitted.
Statistical analysis
The w
2 test and Fisher’s exact test (two-sided) were used to
examine the correlation between the expression of Fos proteins
and clinicopathologic factors (age, FIGO-stage, histology, grade,
CA-125). For statistical analysis, the cases were divided into three
equal groups representing low, moderate and high expression of
the analysed transcription factor. These groups were compared
with the clinicopathological factors tumour stage (FIGO I/II vs III
vs IV), residual tumour after surgery (o1 vs X1cm), grading (G1/
G2 vs G3), age (o65 vs X65 years), histological subtype (serous vs
endometrioid/mucinous vs others) and CA125 serum level (below
vs above median). Survival curves were plotted using the Kaplan–
Meier method and differences between survival curves were tested
using the log-rank test. For multivariate analysis, Cox regression
analysis was performed. Probability values less than 0.05 were
regarded as statistically significant. All statistical analyses were
conducted using SPSS software Version 15 (SPSS Inc., Chicago, IL,
USA).
RESULTS
Patients
A total of 101 patients were included in this study; detailed
characteristics are listed in Table 1. All patients underwent radical
surgery including hysterectomy, bilateral salpingo-oophorectomy,
appendectomy, infragastric omentectomy and systematic pelvic
and paraaortic lymphadenectomy as well as resection of all visible
tumour. In the majority of patients, optimal debulking could be
achieved (67 patients with microscopic residual tumour and 17
patients with residual tumour o1cm). Ninety-six patients
received platinum-based first-line chemotherapy, predominantly
in combination with a taxane; six patients were treated with 2–3
preoperative (neoadjuvant) cycles of chemotherapy as part of a
phase II trial. Median follow up time was 20 months.
In the study cohort, progression-free survival ranged between
0.4 and 98 months with a median of 15.2 months; median overall
survival was 20 months and ranged from 0.4–98 months.
Expression of c-Fos, FosB, Fra-1 and Fra-2 in ovarian
carcinomas
A representative western blot analysis of c-Fos, FosB, Fra-1 and
Fra-2 expression is shown in Figure 1. As control, proteins
extracted from the ovarian cancer cell lines Ovcar5 and Ovcar8 as
well as the mammary carcinoma cell line MCF7 were included in
each gel.
C-Fos expression varied extensively in different samples with a
strong signal at around 55kDa in MCF7 and Ovcar5 cells and some
carcinomas, whereas the signal was only weak or undetectable in
Ovcar8 cells and other tumours. Compared to the expression in
Ovcar5 cells, which was defined as 100%, c-Fos expression ranged
between 0.8 and 283% (mean 38.5%, median 21.3%) in the tumour
samples.
As the protein extracts used in this study contained not only
carcinoma cells, but also varying portions (o30%) of stromal
fibroblasts, we performed immunohistochemistry with paraffin
sections of 14 tumours to find out which cells are expressing the
c-Fos protein. In most cases, nuclear c-Fos immunostaining was
found in 2–50% of tumour cells (Figure 2), but cytoplasmic
staining was also seen in some cases. In addition, weak-to-
moderate nuclear c-Fos reactivity was observed in 10–50% of
stromal fibroblasts.
FosB was detected as 1 or 2 bands at 48–55kDa, with high
expression in Ovcar5 and MCF7 cells, low protein expression in
Ovcar8 cells and strong variations in the tumour samples. Results
of densitometry ranged between 2 and 2307% when FosB
expression in Ovcar5 was set as 100% (mean 236%, median
112%). The smaller splice product FosB2 was detected on the same
membranes as a weak signal in most tumours (not shown).
Fra-2 was strongly expressed in Ovcar8 cells and most ovarian
tumours. Owing to posttranslational phosphorylation, it was
detected as 2–4 bands at 38–47kDa. Compared to Ovcar8, the
c-Fos
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Figure 1 Representative results of c-Fos, FosB, Fra-1 and Fra-2
expression in ovarian carcinomas. As control, protein extracts from the
ovarian cancer cell lines Ovcar5 and Ovcar8 as well as the mammary
carcinoma cell line MCF7 were included in each gel. Tumour samples were
coded as Txxxx and equal amounts of protein (20mg) were loaded on the gel.
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smean expression level after densitometry was 154% (range 5–
480%, median 130%).
Fra-1 expression was extremely strong in Ovcar8 cells, but
relatively weak in the analysed tissue samples. Owing to back-
ground staining and only weak Fra-1-specific bands, densitometric
evaluation of band intensity could not be performed. Instead, Fra-1
expression was scored semiquantitatively as negative (n¼8), low
(n¼47), moderate (n¼27) or strong (n¼19).
Correlation of Fos protein expression with
clinicopathological parameters
Correlations between Fos protein expression and clinicopatho-
logical factors are listed in Table 2. A statistically significant
correlation could be observed between expression of c-Fos and
FosB. Loss of c-Fos expression was significantly more frequent in
high-grade carcinomas. Expression of FosB correlated with Fra-1
expression, but no statistically significant correlations could be
observed for FosB, Fra-1, Fra-2 and the other clinicopathologic
factors evaluated.
For the FosB splice variant FosB2 and single Fra-1 and Fra-2
bands representing the differentially phosphorylated proteins, a
separate densitometric evaluation and statistical analysis was
performed as described for the other Fos proteins. However, no
significant correlations with histological or clinicopathological
factors were found (not shown).
Correlation of c-Fos expression with progression-free
survival and overall survival
Reduced c-Fos expression was associated with significantly shorter
progression-free survival (20.6, 31.6 and 51.2 months for patients
with low, moderate and high c-Fos expression; P¼0.003). The
same could be observed for overall survival with 23.8, 46.0 and 55.5
months for low, moderate and high c-Fos levels (P¼0.003,
Figure 3). These results did not change, when patients with
neoadjuvant chemotherapy (n¼6) were excluded from the
analysis. For FosB, Fra-1 and Fra-2, no associations with survival
were found (not shown). In addition to the prognostic function of
c-Fos, univariate analysis revealed a statistically significant impact
on survival for CA-125 level before surgery, histological subtype,
FIGO-stage and residual tumour after surgery (Table 3).
Subsequently, a multivariate Cox regression analysis including
c-Fos, residual tumour, FIGO-stage, histological subtype and
preoperative CA-125 serum levels was performed. Reduced c-Fos
expression, residual tumour X1cm and advanced FIGO-stage
were associated with significantly shorter progression-free survi-
val. Furthermore, c-Fos expression and residual tumour were
independently associated with poor overall survival (Table 4).
DISCUSSION
To investigate the function and prognostic significance of
Fos-proteins in epithelial ovarian carcinoma, we analysed the
expression of c-Fos, FosB, Fra-1 and Fra-2 in 101 patients with
invasive epithelial carcinoma of the ovary. We could demonstrate
for the first time that loss of c-Fos expression correlates with
disease progression and c-Fos might be an independent prognostic
factor in ovarian carcinoma.
The results of our study are in contrast to the mainstream
opinion concerning the oncogenic function of c-Fos, but an
increasing number of recent experimental and clinical reports
support our findings (Teng, 2000). Growing evidence from in vitro
and in vivo studies suggests that c-Fos might actually be able to do
both, promote and suppress tumorigenesis. This double action
could be enabled by differential protein composition of tumour
cells and their environment, for example, dimerisation partners,
co-activators and promoter architecture.
Decreased c-Fos expression was observed in metastatic
mammary carcinoma cell lines compared to non-metastatic cells
(Kustikova et al, 1998). In tissue samples of human non-small cell
lung cancer and thyroid carcinoma, c-Fos expression was
significantly lower compared to normal tissue (Levin et al, 1995;
Liu et al, 1999). Recently, an immunohistochemical study
including more than 600 patients with gastric carcinoma could
demonstrate that loss of c-Fos expression was associated with
adverse outcome (Jin et al, 2007).
One possible explanation for the tumour-suppressor activity of
c-Fos could be a proapoptotic function, which might confer
increased chemoresistance to tumours with low c-Fos protein
A B
S
S
T
T
Figure 2 C-Fos immunohistochemistry. (A) Moderately differentiated serous carcinoma with nuclear immunoreactivity in tumour cells (T) and weak
immunostaining in nuclei of some stromal fibroblasts (S). 400 .( B) Poorly differentiated serous carcinoma with only weak c-Fos immunostaining in tumour
cells (T) and some fibroblasts (S). 400 .
Table 2 Correlations of Fos proteins with clinical/pathological variables
(P-values) and with each other
c-Fos FosB Fra-1 Fra-2
Age 0.431 0.715 0.167 0.139
Grading 0.038
a 0.149 0.384 0.469
FIGO stage 0.586 0.162 0.709 0.633
Histologic Subtype 0.393 0.206 0.674 0.372
CA-125 0.911 0.306 0.881 0.062
FosB 0.001 — — —
Fra-1 0.058 0.003 — —
Fra-2 0.403 0.095 0.593 —
aInverse correlation.
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slevels. Induction of c-Fos results in apoptosis in murine
hepatocytes that conditionally express c-Fos (Mikula et al, 2003).
Fos
 / tp53
 /  double-knockout mice develop highly invasive and
proliferative rhabdomyosarcoma, a tumour rarely observed in
tp53
 /  knockout-mice (Fleischmann et al, 2003). Of note, re-
expression of c-Fos in an established tumour cell line from these
mice increased apoptosis. The exact mechanisms by which c-Fos
contributes to apoptosis are poorly understood. Elevated c-Fos
expression is associated with concomitant activation of the AP-1
transcription factor complex (Schadendorf et al, 1996; Schaerli and
Jaggi, 1998; Huang et al, 2003). AP-1 activity has been mainly
associated with cell proliferation and tumour progression, but
there is increasing evidence that AP-1 might also have an
important function in cell death (Shaulian and Karin, 2001). The
ability of AP-1 to participate in several different cellular processes
requires activation of different target genes under different
conditions. It is possible that changes in the composition of
AP-1 are essential in cellular response to different stimuli.
Observations in human hepatocellular carcinoma cells indicate
that c-Fos is a mediator of c-myc-induced cell death and might
induce apoptosis through the p38 MAP kinase pathway (Kalra and
Kumar, 2004). Fas ligand (FASLG or FasL) and the tumour
necrosis factor-related apoptosis-inducing ligand (TNFSF10 or
TRAIL) might reflect an additional apoptotic mechanism induced
by c-Fos, as observed in a human T-cell leukaemia cell line
(Siegmund et al, 2001). Another possible mechanism of c-Fos
involvement in tumour suppression could be the direct regulation
of BRCA1, a well established factor in familial breast and ovarian
cancer (Graves et al, 2007).
In ovarian cancer, indirect evidence of a possible antioncogenic
function of c-Fos has recently been described. Appierto et al.
(2004)could observe an involvement of c-Fos in fenretinide-
induced apoptosis in human ovarian carcinoma cells. In their
study, apoptosis was accompanied by elevation of c-Fos expression
at mRNA and protein level. This observation supports our results,
which demonstrate an association of reduced c-Fos expression
with adverse outcome (Figure 3, Tables 3 and 4).
The correlation between low-grade tumours and high c-Fos
expression that we observed could also be demonstrated in a
molecular comparison between serous ovarian carcinomas of
varying grade and borderline (low malignant potential, LMP)
tumours (Meinhold-Heerlein et al, 2005). In that series, c-Fos
mRNA levels were significantly higher in LMP and low-grade
tumours compared to intermediate and high-grade carcinomas.
Analogue findings were observed in a comparative analysis of gene
expression profiles in normal and neoplastic ovarian tissue
samples (Welsh et al, 2001): c-Fos was highly expressed in normal
tissues and weakly expressed in tumours. Although normal tissues
and LMP tumours were not included in our study, we observed the
same results for invasive carcinomas of varying grade (Table 2).
The improved outcome we noticed with increased expression of
c-Fos could also imply that ovarian carcinomas are more
susceptible to treatment, when c-Fos is activated. This hypothesis
is supported by the observation that patients with advanced
colorectal carcinoma had higher response rates to cytostatic
treatment and improved survival, when intratumoral c-Fos
expression was high (Singh et al, 1998). However, the results of
Progression-free survival
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Figure 3 C-Fos expression is correlated with progression-free and overall survival (P¼0.003). Kaplan–Meier curves were generated from 99 patients
whose outcome was followed over a median period of 20 months. Patients were stratified based on low, moderate and high c-Fos expression. X axis:
survival probability; Y axis: survival (months). Censored cases are indicated by vertical bars.
Table 3 Univariate Kaplan–Meier analysis of clinicopathological factors
in relation to progression-free survival (A) and overall survival (B)
Progression-free survival Overall survival
Factor P-value P-value
Age 0.415 0.92
CA-125 0.008 0.082
Histology 0.016 0.039
FIGO stage 0.001 0.048
Residual tumour o0.001 o0.001
Grading 0.475 0.896
FIGO¼International Federation of Gynecology and Obstetrics.
Table 4 Multivariate Cox regression analysis including c-Fos expression,
residual tumour, FIGO stage, histologic subtype, and preoperative CA-125
serum levels to determine the impact on progression-free survival (A) and
overall survival (B)
Progression-free survival
A HR 95% CI P-value
c-Fos 0.554 0.353–0.870 0.010
Residual tumour 4.824 1.226–18.990 0.024
FIGO stage 1.917 1.013–3.628 0.046
Histology 1.032 0.548–1.942 0.922
CA-125 1.936 0.888–4.222 0.097
Overall survival
B HR 95% CI P-value
c-Fos 0.546 0.310–0.961 0.036
Residual tumour 6.022 1.697–21.369 0.005
FIGO stage 1.390 0.589–3.277 0.452
Histology 1.048 0.493–2.228 0.903
CA-125 1.589 0.637–3.967 0.321
CI¼confidence interval; FIGO¼International Federation of Gynecology and
Obstetrics; HR¼hazard ratio.
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sour study cannot determine whether the positive prognostic effect
of c-Fos is the result of intrinsic differences in malignant potential
of the tumours or of differences in chemo-resistance.
Findings of previous experimental studies suggested that Fra-1
expression might also have a function in ovarian cancer (Hapke et al,
2003; Tchernitsa et al, 2004). However, our results could not show an
impact of Fra-1, Fra-2 and FosB on ovarian cancer progression.
Limitations of our study are its retrospective monocentric
nature and the fact that tumour tissue was not strictly collected in
consecutive patients, leading to a possible selection bias. However,
the high number of patients with optimal surgical cytoreduction
and thorough surgical staging followed by platinum-based
combination chemotherapy might be a strength of this study: In
the presence of large residual tumours after primary surgery,
progression mainly occurs due to selection of resistant tumour
clones during first-line chemotherapy. Biological factors leading to
true primary chemo-resistance and progression are more likely to
have a function if only microscopic residual tumour is present.
In summary, this report documents that loss of c-Fos expression
is significantly and independently associated with reduced
progression-free and overall survival in a cohort of optimally
treated patients with epithelial ovarian cancer. These results
suggest for the first time that c-Fos might have a function in
tumour suppression in ovarian cancer. It may be clinically useful
for stratification of platinum-resistant patients but additional
studies are needed to confirm our findings and assess the
underlying molecular mechanisms.
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